Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
HHS newborn screening panel: Recommendation that all newborns be screened for 29 rare medical conditions will be discussed when the Advisory Committee on Heritable Disorders & Genetic Diseases in Newborn & Children convenes April 21-22 in Washington, D.C. A report elucidating the proposed recommendations will be published the week of Feb. 28 in the Federal Register, with comments due the week of May 1. The committee has dropped a test for G6PD deficiency from the recommended test panel, citing insufficient evidence to justify screening (1"The Gray Sheet" Sept. 27, 2004, p. 6)...
You may also be interested in...
Expanded Newborn Screening Recommended By HHS Advisory Committee
HHS is one step closer to establishing national guidelines advising which tests should be added to state-mandated newborn screening programs
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.